The acquisition, as per HMI, will help it to tap into the digital healthcare space in Southeast Asia, which has an estimated market size of $11 billion by 2027, and give the combined group a revenue base of over S$350 million.
The consortium will pay about $43 per share in cash, which represents a premium of about 12 per cent to Syneos' last close. The acquisition is valued at $7.1 billion including debt. North Carolina-based Syneos has been facing challenges in winning new business as many of its clients, which include small and medium-sized biotech companies, have cut spending amid difficulties raising funding in a post-COVID market downturn.
NARCL has offered ₹45 crore against a claim of ₹1,173 crore that these two banks have filed with the resolution professional, according to a notice issued by lenders to other ARCs. Parenteral Drugs was admitted by National Company Law Tribunal (NCLT) for corporate insolvency in February this year.
SOBI said it would make a tender offer for $9.10 per CTI share, a premium of 89 per cent over Tuesday's closing price of $4.82. As per the company the planned transaction, which was unanimously recommended by CTI's board, is fully funded through debt financing, up to half of which is expected to be refinanced through a rights issue.
The purchase price for the acquisition exceeds 100 million euros ($110.47 million), Wacker Chemie said in a statement.
Jamjoom Pharma plans to list on the Saudi Exchange's main market by selling 21 million of its existing shares, equivalent to 30 per cent of its issued shared capital, the company said in a statement. JPMorgan Saudi Arabia and Saudi Fransi Capital are financial advisers for the IPO. They are joined as underwriters and book runners by AlRajhi Capital. Saudi Fransi Capital is also the lead manager.
MyAva is a startup, which empowers women to manage chronic health conditions like polycystic ovary syndrome (PCOS), thyroid disorders, insulin resistance and more. Bonatra is a startup focused on treating and managing chronic diseases, such as diabetes, Hypertension, fatty liver, PCOD, Obesity etc.
Following the acquisition about 10 per cent of consolidated revenue will come from healthcare, the company said, adding it expects the deal to close by the end of the third quarter. DuPont also beat analysts' estimates for first-quarter profit, as it benefited from strong demand in its water and protection segment, as well as price increases.
Qwazent launched its innovative recruitment platform, Hyre last year which is an AI-driven platform to combine human capability transparently with data analytics to deliver the best-suited candidates for clients. Qwazent is known for its expertise and commitment to delivering exceptional results for its clients.
The acquisition will give Sonic access to MLD's hub-and-spoke infrastructure around its central laboratory, including several branch and hospital sites across Germany's Duesseldorf metropolitan region. Sonic will be funding the buyout, expected to immediately add to its earnings per share, from existing cash and debt facilities.
The acquisition of Aveva Drug Delivery Services Inc with its 300 plus employees marks an important milestone for DifGen as it adds its first pharmaceutical manufacturing base in the US. Norton Rose Fulbright US LLP represented DifGen Pharmaceuticals in this transaction.
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
